Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of ivonescimab after targeted TKI resistance in AGA-positive nonsquamous NSCLC
CTR20253268Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- Aug 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Akeso, Inc.. Started Aug 2025; status: active.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20253268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253268.